January 2025 in “Acta Dermatovenerologica Alpina Pannonica et Adriatica” JAK inhibitors can help regrow hair in alopecia areata but have potential long-term risks and require careful monitoring.
3 citations
,
February 2025 in “Journal of Dermatological Treatment” Hair regrowth in Alopecia Areata patients leads to increased satisfaction and reduced stress.
Baricitinib helps regrow hair in teens with severe alopecia areata.
20 citations
,
December 2021 in “Journal of the American Academy of Dermatology” Continuous treatment with ritlecitinib and brepocitinib is needed to maintain hair regrowth in alopecia areata.
High CCL11 levels may indicate poor response to baricitinib in severe alopecia areata.
August 2025 in “Dermatology and Therapy” JAK inhibitors show promise for treating alopecia areata but have serious side effects.
February 2024 in “Journal of the European Academy of Dermatology and Venereology” Baricitinib is effective and safe for long-term use in severe alopecia areata, improving hair regrowth and quality of life with few side effects.
86 citations
,
January 2020 in “British Journal of Dermatology” The AA-IGA scale reliably measures treatment success in alopecia areata by considering both clinician and patient views.
2 citations
,
April 2025 in “Biologics” Dupilumab and ustekinumab are promising treatments for alopecia areata, showing significant hair regrowth.
June 2026 in “Journal of health economics and outcomes research” Ritlecitinib is more effective and cost-efficient than baricitinib for severe alopecia areata.
September 2025 in “Australasian Journal of Dermatology” New medications could improve treatment for severe alopecia areata in Australia.
May 2023 in “Journal of Clinical Medicine” New understanding and treatments for hair loss are improving, but more research is needed.
8 citations
,
June 2022 in “Frontiers in Medicine” Both individual and combined treatments of tofacitinib and corticosteroids can help regrow hair in moderate-to-severe alopecia areata, but ongoing treatment may be necessary.
January 2026 in “Journal of Dermatology Research and Therapy” Combination therapy effectively regrows hair and reduces severity in Black children with stubborn Alopecia Areata.
January 2025 in “Dermatologic Therapy” Baricitinib effectively promotes hair regrowth in alopecia areata patients with mild side effects.
JAK inhibitors effectively regrow hair in children with alopecia areata and are safe to use.
March 2025 in “Journal of Clinical Medicine” Iron chelators can effectively reduce hair loss and improve hair growth in autoimmune alopecia.
15 citations
,
January 2022 in “Immune Network/Immune network” New targeted immunotherapies are improving treatment for inflammatory skin diseases.
72 citations
,
March 2023 in “Biomolecules” Dupilumab effectively treats various inflammatory skin diseases beyond its initial use for atopic dermatitis.
3 citations
,
September 2025 in “Frontiers in Immunology” JAK inhibitors are effective for treating moderate-to-severe alopecia areata.
February 2026 in “Journal of the American Academy of Dermatology” Ophiasis mainly affects females, lasts longer, and has lower regrowth rates, with a new classification system helping predict treatment response.
September 2025 in “Frontiers in Immunology” Atopic dermatitis and alopecia areata share immune and genetic factors, and targeted therapies may help both.
July 2023 in “IntechOpen eBooks” New treatments for alopecia areata show promise, but more research is needed to confirm their effectiveness.
January 2023 in “Indian Dermatology Online Journal” No single ideal JAK inhibitor for alopecia areata has been determined; JAK3 inhibitors may be promising with fewer side effects.
June 2026 in “Wiener klinische Wochenschrift” New treatments for alopecia areata show promise but need ongoing use and have infection risks.
91 citations
,
May 2023 in “Journal of Cutaneous Medicine and Surgery” Alopecia Areata affects 2% globally, with treatments like essential oils, garlic, and JAK inhibitors showing promise, but more research is needed.
4 citations
,
September 2022 in “Dermatologic Therapy” Baricitinib helped some patients with tough-to-treat hair loss regrow hair, but more research is needed on its safety.
1 citations
,
April 2025 in “Experimental Dermatology” Topical ruxolitinib may help some skin conditions but needs more research for alopecia areata.
September 2025 in “International Journal of Molecular Sciences” International guidelines for treating alopecia areata vary, focusing on different treatment options and related health issues.
New hair regrowth therapies show promise but need more research.